Obesity drugs may protect brain function beyond weight loss

Medications such as "semaglutide" and "tirzepatide," currently prescribed for obesity and type 2 diabetes, may also impact brain function according to recent scientific reviews. A new study published in the journal "Science" indicates that while these drugs show potential effects on learning and memory in animal models, human results remain mixed and inconclusive.

Unclear Cognitive Impact

Researchers note that studies relying on patient records have identified a link between "GLP-1" treatments and a reduced risk of dementia among individuals with type 2 diabetes. However, these observational data do not confirm that the medication is the direct cause of the lowered risk. In clinical trials named "EVOKE" and "EVOKE+" conducted by Novo Nordisk, semaglutide failed to slow the progression of early Alzheimer's disease, despite showing changes in certain biological markers associated with the condition.

The scientific community has yet to determine whether these drugs improve brain function indirectly through better metabolism and vascular health, act directly on neural processes, or achieve both outcomes simultaneously. Stina Borchers, the lead author of the review, emphasized the need to understand if these therapies can help patients with obesity or diabetes maintain their cognitive abilities, particularly if treatment begins before any cognitive issues appear.

Potential Beneficiary Groups

Borchers added that identifying which specific patients would truly benefit from these medications remains a priority. The researchers suggest that the groups most likely to see advantages include those suffering from obesity, type 2 diabetes, or existing difficulties with attention, planning, and mental processing speed. These cognitive challenges are often tied to metabolic or vascular disorders, making them potentially more responsive to treatment than Alzheimer's disease itself.

Christopher Klemensen, the senior author of the review, stated that obesity drugs have become more sophisticated, opening new opportunities to explore the relationship between metabolic regulation and brain function. He noted that distinguishing between the direct and indirect effects of these medications could lead to personalized treatments designed to preserve cognitive capabilities.

Risks and Monitoring Needs

The authors stressed the importance of conducting clinical trials that track memory and cognitive skills from the start of therapy. They also highlighted the necessity of monitoring older and physically frail patients, as rapid weight loss and muscle mass reduction could impair physical function and diminish the expected benefits of the treatment. Current evidence suggests users of slimming medications may face deficiencies in essential nutrients, further complicating the assessment of long-term neurological impacts.